Murine cytomegalovirus retinitis during MAIDS: Susceptibility correlates with elevated intraocular levels of interleukin-4 mRNA

References

• Cunningham ET, Margolis TR Ocular manifestations of HIV infection. N Engl J Med. 1998;339:236–244.
   PubMed Web of Science ®Google Scholar
• Bloom JN, Palestine AG. The diagnosis of cytomegalovirus retinitis. Ann Intern Med. 1988;15:963–969.
   Web of Science ®Google Scholar
• Fay MT, Freeman WR, Wiley CA, Hardy D, Bozzette S. Atypical retinitis in patients with the acquired immunode-ficiency syndrome. Am J Ophthalmol. 1988;105:483–490.
   Google Scholar
• Jabs DA, Enger C, Bartlett JG. Cytomegalovirus retinitis and acquired immunodeficiency syndrome. Arch Ophthal-mol. 1989;107:75–80.
   PubMed Web of Science ®Google Scholar
• Jabs DA, Bartlett JG. AIDS and ophthalmology: A period of transition. Am J Ophthalmol. 1997;124:227–233.
   PubMed Web of Science ®Google Scholar
• Palella FJ Jr, Delaney KM, Moorman AC, Loveless JO, Fuhrer J, Satten DJ, Aschman J, Homberg SD, and the HIV Outpatient Study. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853–860.
   Google Scholar
• Jacobson MA, Stanley S, Holtzer C, Margolis TP, Cunningham ET. Natural history and outcome of new AIDS-related cytomegalovirus retinitis diagnosed in the era of highly active antiretroviral therapy. Clin Infect Dis. 2000;30:232–233.
   Google Scholar
• Dix RD, Cray C, Cousins SW. Mice immunosuppressed by murine retrovirus infection (MAIDS) are susceptible to cytomegalovirus retinitis. Curr Eye Res. 1994;13:587–595.
   Google Scholar
• Morse III HC, Chattopadhyay SK, Makino M, Fredrickson TN, Hugin AW, Hartley JIM Retrovirus-induced immunod-eficiency in the mouse: MAIDS as a model of AIDS. AIDS. 1992;6:607–621.
   PubMed Web of Science ®Google Scholar
• Dix RD, Giedlin M, Cousins SW. Systemic cytokine immunotherapy for experimental cytomegalovirus retinitis in mice with retrovirus-induced immunodeficiency. Invest Ophthalmol Vis Sci. 1997;38:1411–1417.
   Google Scholar
• Smith KA. Interleukin-2: Inception, impact, and implica-tions. Science. 1988;240:1169–1176.
   PubMed Web of Science ®Google Scholar
• Kagi D, Vignaux F, Ledermann B, Burki K, Depraitere V, Nagata S, Hengartner H, Golstein P. Fas and perforM path-ways as major mechanisms of T cell-mediated cytotoxicity. Science. 1994;265:528–530.
   PubMed Web of Science ®Google Scholar
• Smyth MJ, Trapani JA. The relative role of lymphocyte granule exocytosis versus death receptor-mediated cyto-toxicity in viral pathophysiology. J Virol. 1998;72:1–9.
   PubMed Web of Science ®Google Scholar
• Dix RD, Podack ER, Cousins SW. Loss of the perform cytotoxic pathway predisposes mice to experimental cytomegalovirus retinitis. J Virol. 2003; (in press).
   Google Scholar
• Dix RD, Podack ER, Cousins SW. Murine cytomegalovirus retinitis during retrovirus-induced immunodeficiency in mice (MAIDS): Interleukin-2 immunotherapy correlates with increased intraocular levels of perform mRNA. Antiviral Res 2003; (in press).
   Google Scholar
• Clerici M, Shearer GM. A TH1-TH2 switch is a critical step in the etiology of HIV infection. Immunol Today. 1993;14:107–111.
   PubMedGoogle Scholar
• Villacres M, Bergmann CC. Enhanced cytotoxic T cell activity in IL-4-deficient mice. J Immunol. 1999;162:2663–2670.
   PubMed Web of Science ®Google Scholar
• Aung S, Graham BS. IL-4 diminishes perforM-mediated and increases Fas ligand-mediated cytotoxicity in vivo. J Immunol. 2000;164:3487–3493.
   PubMed Web of Science ®Google Scholar
• Gazzinelli RT, Makino M, Chattopadhyay SK, Snapper CM, Sher A, Hugin AW, Morse III HC. CD4+ subset regulation in viral infection: Preferential activation of Th2 cells during progression of retrovirus-induced immunodeficiency in mice. J Immunol. 1992;148: 182–188.
   Google Scholar
• Deng G, Podack ER. Suppression of apoptosis in a cyto-toxic T-cell line by interleukin-2-mediated gene transcrip-tion and deregulated expression of the protooncogene bc1-2. Proc Nall Acad Sci USA. 1993;90:2189–2193.
   PubMed Web of Science ®Google Scholar
• Bustin SA. Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J Mol Endocrinol. 2000;25:169–193.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA. Progress in the development of immunotherapy for the treatment of patients with cancer. J Intern Med. 2001;250:462–475.
   PubMed Web of Science ®Google Scholar
• Atkins MB. Interleukin-2: Clinical applications. Seminars in Oncology. 2002;29:12–17.
   PubMed Web of Science ®Google Scholar
• Kovacs JA, Vogel S, Albert TM, Falloon J, Davey RT Jr, Walker RE, Polis MA Spooner K, Metcalf JA, Baseler M, Fyfe G, Lane HC. Controlled trial of interleukin-2 infusions in patients with the human immunodeficiency virus. N Engl J Med. 1996;335:1350–1356.
   Google Scholar
• Davey RT Jr, Chaitt DG, Albert TM, Piscetelli SC, Kovacs JA, Walker RE, Falloon J, Polis MA, Metcalf JA, Masur H, Dewar R, Baseler M, Fyfe G, Giedlin MA, Lane HC. A randomized trial of high- versus low-dose subcutaneous interleukin-2 outpatient therapy for early immunodefi-ciency virus type 1 infection. J Infect Dis. 1999;179: 849–858.
   Google Scholar
• Kovacs JA, Vogel S, Metcalf JA, Baseler M, Stevens R, Adelsberger J, Lempicki R, Hengel RL, Sereti I, Lambert L, Dewar RL, Davey RT Jr, Walker RE, Falloon J, Polis MA, Masur H, Lane HC. Interleukin-2 induced immune effects in human immunodeficiency virus-infected patients receiving intermittent interleukin-2 immunotherapy. Eur J Immunol. 2001;31: 1351–1360.
   Google Scholar
• Mitsuyasu RT. The potential role of interleukin-2 in HIV. AIDS. 2001;15(Suppl 2):S22–S27.
   Google Scholar
• Aung S, Tang Y-W, Graham BS. IL-4 diminishes CD8+ respiratory syncytial virus (RSV)-specific cytotoxic T lymphocyte activity in vivo. J Virol. 1999;73: 8944–8949.
   Google Scholar
• Fischer JE, Johnson JE, Kuli-Zade RK, Johnson TR, Aung S, Parker RA, Graham BS. Overexpression of interleukin-4 delays virus clearance in mice infected with respiratory syncytial virus. J Virol. 1997;71: 8672–8677.
   Google Scholar
• Moran TM, Isobe H, Fernandez-Sesma A, Schulman JL. Interleukin-4 causes delayed viral clearance in influenza virus-infected mice. J Virol. 1996;70: 5230–5235.
   Google Scholar
• Sharma EP, Ramsay AJ, Maguire DJ, Rolph MS, Ramshaw IA. Interleukin-4 mediates down regulation of antiviral cytokine expression and cytotoxic T-lymphocyte responses and exacerbates vaccinia virus infection in vivo. J Virol. 1996;70: 7103–7107.
   Google Scholar
• Aung S, Graham BS. IL-4 diminsihes perforM-mediated and increases Fas ligand-mediated cytotoxicity in vivo. J Immunol. 2000;164:3487–3493.
   PubMed Web of Science ®Google Scholar
• Cousins SW, Rouse BT. Chemical mediators of ocular inflammation. In Ocular Infection & Immunity (Eds Pepose JS, Holland GN, Wilhelmus KR). Pp. 50–70, Mosby Press, St. Louis, MO. 1996.
   Google Scholar
• Charteris DG, Lightman SL. Comparison of the expression of interferon gamma, IL2, IL4, and lymphotoxin mRNA in experimental autoimmune uveoretinitis. Br J Ophthalmol. 1994;78:786–790.
   PubMed Web of Science ®Google Scholar
• Keino H, Takeuchi J, Suzuki J, Kojo S, Sakai J, Nishioka K, Sumida T, Usui M. Identification of Th2-type suppres-sor T cells among in vivo expanded ocular T cells in mice with experimental autoimmune uveoretinitis. Clin Exp Immunol. 2001;124:1–8.
   PubMed Web of Science ®Google Scholar
• Verjans GMGM, Feron EJ, Dings MEM, Cornelissen JGC, Van der Lelij A, Baarsman GS, Osterhaus ADME. T cells specific for the triggering virus infiltrate in the eye in patients with herpes simplex virus-mediated acute retinal necrosis. J Infect Dis. 1998;178:27–34.
   Google Scholar
• Ghiasi H, Cai S Slanina SM, Guey-Chuen P, Nesburn AB, Wechsler SL. The role of interleukin (IL)-2 and IL-4 in herpes simplex virus type 1 ocular replication and eye disease. J Infect Dis. 1999;179:1086–1093.
   Google Scholar
• Sad S, Mosmarm TR. IL-4, in the absence of antigen stimulation, induces an anergy-like state in differentiated CD8+ Tc 1 cells, loss of IL-2 synthesis and autonomous proliferation but retention of cytotoxicity and synthesis of other cytokines. J Exp Med. 1995;182:1505–1511.
   PubMed Web of Science ®Google Scholar